1. Home
  2. BLNK vs NKTX Comparison

BLNK vs NKTX Comparison

Compare BLNK & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$1.21

Market Cap

129.3M

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$1.80

Market Cap

126.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
NKTX
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.3M
126.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BLNK
NKTX
Price
$1.21
$1.80
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$2.13
$13.25
AVG Volume (30 Days)
2.3M
680.2K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,631,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.31
52 Week High
$2.65
$2.79

Technical Indicators

Market Signals
Indicator
BLNK
NKTX
Relative Strength Index (RSI) 37.12 42.86
Support Level $1.24 $1.77
Resistance Level $1.43 $1.93
Average True Range (ATR) 0.10 0.08
MACD 0.01 0.01
Stochastic Oscillator 6.90 45.65

Price Performance

Historical Comparison
BLNK
NKTX

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: